2005 News Archive


12/21/2005 Adherex Receives FDA Orphan Drug Designation for Eniluracil in Liver Cancer
11/28/2005 Adherex Receives IND Clearance from the FDA for Eniluracil
11/16/2005 Adherex Announces Global Development Plans for Advancing Eniluracil into Phase III by Mid 2007
11/8/2005 Adherex to Present Data at Rodman & Renshaw Conference Indicating Broad Presence of ADH-1 Target on Multiple Cancers
11/7/2005 Adherex Reports Third Quarter 2005 Financial Results
10/27/2005 Adherex to Release Global Development Plans for Eniluracil on November 16 Conference Call
8/10/2005 Adherex Reports Second Quarter 2005 Financial Results
8/3/2005 Adherex Initiates Two Additional Sites for Phase II ADH-1 Trial
7/28/2005 Adherex to Present at America's Growth Capital Conference
7/20/2005 Adherex Announces Closing of US$8.5 Million Private Placement
7/15/2005 Adherex Announces Licensing Deal with GlaxoSmithKline
6/23/2005 Adherex Announces US$9 million Private Placement Pending Licensing Agreement Completion
5/16/2005 Adherex Presents Final Clinical Data on ADH-1 Phase I Trial at ASCO Annual Meeting
5/12/2005 Adherex Initiates U.S. Phase Ib/II Trial of ADH-1
5/11/2005 Adherex Initiates Phase II Trial of ADH-1
5/10/2005 Adherex Reports First Quarter 2005 Financial Results
4/14/2005 Adherex Announces Presentations on ADH-1 at AACR
3/24/2005 Adherex Receives Regulatory Clearance for Phase II Trial of ADH-1 in Canada
3/23/2005 Adherex and Scynexis Sign Agreement to Accelerate Design of Small Molecule Antagonists
3/21/2005 Adherex Reports 2004 Six-Month Fiscal Transition Results
3/14/2005 Adherex to Present at NCI's Cancer Therapy Evaluation Program Early Drug Development Meeting
3/11/2005 Adherex and National Cancer Institute to Collaborate on Clinical Development of ADH-1
2/22/2005 Adherex To Present At BIO CEO & Investor Conference 2005
2/15/2005 Adherex To Hold Conference Call to Update Clinical Programs
2/14/2005 Adherex To Webcast Presentation at NCInvest 2005
1/20/2005 Adherex Announces Change in Fiscal Year End
1/18/2005 Adherex Initiates Phase Ib/II Exherin Trial in Europe